Active surveillance in Oz: a situation report

An interesting article published a couple of week’s ago in the Medical Journal of Australia reports on “real world issues” related to the implementation of active surveillance (AS) in Oz. … READ MORE …

CTC levels as a surrogate endpoint for clinical trials in mCRPC

A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …

Astrology and the interpretation of data from clinical trials

Over the weekend, an  interesting article on clinical trials appeared (somewhat unexpectedly) in the New York Times color supplement. … READ MORE …

“Theranostics” in the management of prostate cancer

The word “theranostics” is a so-called “portmanteau” word made up from the words “therapeutics” and “diagnostics“. Thus, “theranostics” refers to the process of “diagnostic therapy” for individual patients. What exactly do we mean by this? … READ MORE …

Help with finding out about clinical trials for prostate cancer treatment

Apparently the National Cancer Institute (NCI) has just re-funded the Fred Hutchinson Cancer Research Center in Seattle to the tune of $24 million to continue to operate what we see as an important, patient-centric program here in the USA that we (and therefore probably many others) were utterly unaware of. … READ MORE …

Clinical and therapeutic histories of men who actually die of mCRPC

Despite all the prostate cancer research over the past 30 or so years, we still have limited information about the clinical and therapeutic history of prostate cancer in men who have progressive disease and go on to die of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Genomic/genetic tests for risk for clinically significant prostate cancer

The precise ability of the various genetic/genomic tests now available to accurately analyze the risk for clinically significant prostate cancer based on biopsy tissue samples is an important factor that all of the different developers and manufacturers of these tests continue to study in greater detail. … READ MORE …